Navigation Links
Innovate Biopharmaceuticals, Targeting Celiac Disease And Ulcerative Colitis, presenting at BIO CEO & Investor Conference
Date:2/8/2017

RALEIGH, N.C., Feb. 7, 2017 /PRNewswire/ -- Executives from Innovate Biopharmaceuticals Inc., which has drug candidates entering Phase 3 and Phase 2 clinical trials, respectively, for the treatments of celiac disease and ulcerative colitis, will be in New York Feb. 13-14, meeting with potential investors at the BIO CEO & Investor Conference. Innovate's presentation is on Monday, Feb. 13, at 2 p.m. EST in the Conrad Room at The Waldorf Astoria.

Interested investors and licensing partners can email the company to schedule meetings: investor.relations@innovatebiopharma.com.

Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate is also developing therapeutics for unmet needs with global impact and for orphan indications.

The company's lead drug candidate for celiac disease, larazotide acetate (INN-202), begins Phase 3 clinical trials in 2017. Larazotide, a novel oral peptide, has been studied in more than 800 patients with results that consistently reduced clinical symptoms of celiac disease. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."

Innovate's second therapeutic, INN-108, enters Phase 2 trials in 2017. INN-108 is a small molecule for the treatment of an adult orphan indication and for mild to moderate ulcerative colitis.  INN-108 is a prodrug that only becomes activated in the colon. An oral liquid formulation is also in development for pediatric and elderly patients.

Licensing opportunities for these drugs are available outside the U.S.

Forward Looking Statements 
This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/innovate-biopharmaceuticals-targeting-celiac-disease-and-ulcerative-colitis-presenting-at-bio-ceo--investor-conference-300403730.html


'/>"/>
SOURCE Innovate Biopharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. VisionGate Receives Strategic Investment from Trinnovate Ventures
2. Phytomer Is Given ISPA Innovate Award for Use of Filtration Garden for the Treatment of Water Waste at 2013 ISPA Conference and Expo
3. NYCEDC Announces Winners of Innovate Health Tech, Highlighting Innovation in NYCs Healthcare Sector
4. The JTB Law Group Continues to Innovate with its New Video Information Series and Vivid Legal Cartoons
5. MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East
6. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
7. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
8. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
9. PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
10. Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
11. ‘Grand Challenge’ targeting prostate lesion diagnostic imaging is launched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... ... June 05, 2019 , ... WCCT Global, Inc ., a full-service ... today that they will be receiving 3 awards at the 2019 CRO Leadership Awards, ... awards in the categories of overall Quality and Compatibility (Access to desired markets, cultural ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... the USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. ... AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. ...
(Date:5/31/2019)... Calif. (PRWEB) , ... May 30, 2019 , ... ... of neurotoxins, is pleased to announce the strategic acquisition of Metabiologics, Inc., a ... The acquisition provides Object exclusive ownership and commercialization rights to a full spectrum ...
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
Breaking Biology Technology:
(Date:6/27/2019)... ... June 27, 2019 , ... Lighting designers from integrated ... Society (IES), which honored the designers for creating both engaging and energy efficient lighting ... Street , an office tower in San Diego, California earned an IES Illumination Award ...
(Date:6/19/2019)... ... 2019 , ... Dahryn Trivedi, today released research results on the beneficial impact ... prove to be beneficial for treating multiple bacterial diseases. , The preclinical trial shows:, ... Over 68% decrease in weight , Over 8% alteration in melting ...
(Date:6/14/2019)... ... June 14, 2019 , ... Molecular diagnostics segment is the fastest-growing segment within ... 2019. Major segments that are expected to drive the growth are infectious diseases, ... as segments in Kalorama’s The World Molecular Diagnostics Market, 8th Edition . , ...
Breaking Biology News(10 mins):